AHZ IPO'd at ~$0.75 and at that valuation, it was:
- Without VascuCel FDA approval
- Without the positive results of the HSV2 trial (rendering AHZ's product best-in-world and probably improvable too)
The share price should be $2 right now - and probably will reach that in an instant as soon as positive revenue announcements start coming.
Look at RAP as a comparison - no revenue, no FDA approval, no one uses telehealth, etc, etc and due to managements' various announcements, the market has shot it up to a MC of $300M!!
AHZ MC is $100M.
Insane.
AHZ IPO'd at ~$0.75 and at that valuation, it was: Without...
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |